Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | YAP1 | P46937 | 2/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433340 | 1.00 | ABCB1 (0.41) | ABCB1YAP1STSL3MBTL1PPARA | |
| SCHEMBL2435097 | 1.00 | ABCB1 (0.41) | ABCB1YAP1STSL3MBTL1PPARA | |
| SCHEMBL5152462 | 0.87 | ABCB1 (0.45) | ABCB1STSL3MBTL1PPARAGPR119 | |
| SCHEMBL14592644 | 0.87 | ABCB1 (0.42) | ABCB1YAP1STSL3MBTL1GPR119 | |
| SCHEMBL19237001 | 0.87 | HTR2C (0.43) | ABCB1STSL3MBTL1PPARAGPR119 | |
| SCHEMBL5457099 | 0.87 | ABCB1 (0.42) | ABCB1YAP1STSL3MBTL1GPR119 | |
| SCHEMBL14592677 | 0.87 | ABCB1 (0.45) | ABCB1STSL3MBTL1PPARAGPR119 | |
| SCHEMBL2433710 | 0.87 | ABCB1 (0.45) | ABCB1STSL3MBTL1PPARAGPR119 | |
| SCHEMBL2432631 | 0.87 | ABCB1 (0.45) | ABCB1STSL3MBTL1PPARAGPR119 | |
| SCHEMBL5162583 | 0.86 | ABCB1 (0.41) | ABCB1STSL3MBTL1PPARAGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. | 2025-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | ABCB1 2205/4885YAP1 614/4885STS 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.